• Mukul Aggarwal, Mirza Saleem Amjad, Akash Khandelwal, Pradeep Kumar, Rishi Dhawan, Jasmita Dass, Kumar Vishwanathan Ganesh, Punit Khanna, Akhil Kant Singh, Kapil Dev Soni, Richa Agarwal, Mohan Bairwa, Arul Selvi, Seema Tyagi, Tulika Seth, Manoranjan Mahapatra, Naveet Wig, and Anjan Trikha.
• Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.
• Indian J Med Res. 2022 May 1; 155 (5&6): 570574570-574.

AbstractThis retrospective study was aimed to understand the clinical, laboratory, radiological parameters and the outcome of COVID-19 patients with underlying haematological disease. All patients with known haematological disease admitted with COVID-19-positive status from April to August 2020 in the COVID-19 facility of a tertiary care centre in north India, were included. Their medical records were analyzed for outcome and mortality risk factors. Fifty four patients, 37 males, were included in the study. Of these, 36 patients had haematological malignancy and 18 had benign disorder. Fever (95.5%), cough (59.2%) and dyspnoea (31.4%) were the most common symptoms. Nine patients had severe disease at diagnosis, mostly malignant disorders. Overall mortality rate was 37.0 per cent, with high mortality seen in patients with aplastic anaemia (50.0%), acute myeloid (46.7%) and lymphoblastic leukaemia (40.0%). On univariate analysis, Eastern Cooperative Oncology Group performance status >2 [odd ratio (OR) 11.6], COVID-19 severity (OR 8.2), dyspnoea (OR 5.7) and blood product transfusion (OR 6.4) were the predictors of mortality. However, the presence of moderate or severe COVID-19 (OR 16.6, confidence interval 3.8-72.8) was found significant on multivariate analysis. The results showed that patients with haematological malignancies and aplastic anaemia might be at increased risk of getting severe COVID-19 infection and mortality as compared to the general population.

18 keywords...

hide…